Axcella Health Inc represents a strong commitment to improving human health through innovative science and research. The company's corporate philosophy revolves around harnessing the power of endogenous metabolic modulators, known as EMMs, to address various metabolic dysregulation conditions. Axcella Health Inc is dedicated to advancing the understanding and utilization of EMMs to develop transformative therapeutics. By leveraging its proprietary platform, this cutting-edge company aims to revolutionize the treatment of complex diseases and enhance overall wellness. With a focus on scientific rigor and clinical evidence, Axcella Health Inc strives to bring novel and effective solutions to patients worldwide.

Axcella Health Inc is primarily present in the United States.

Axcella Health Inc has achieved significant milestones since its inception. Some notable achievements include successfully completing its initial public offering (IPO) in 2019, which raised substantial funding for the company's research and development efforts. Additionally, Axcella Health Inc has made remarkable progress in advancing its innovative pipeline of Multi-Targeted Non-Bioengineered (MTNB) therapeutic candidates. The company has also expanded its collaborative partnerships and collaborations with leading research institutions and organizations. These achievements demonstrate Axcella Health Inc's commitment to revolutionizing therapeutic approaches and advancing the treatment of complex diseases.

Axcella Health Inc is a biotechnology company that specializes in developing transformative therapies to improve the lives of patients. Founded in 2009, the company is focused on harnessing the power of endogenous metabolic modulators (EMMs) to address various diseases and disorders. Axcella Health Inc's innovative approach involves leveraging the body's natural metabolic pathways to restore health and function. With a commitment to scientific rigor and cutting-edge research, the company aims to bring novel treatment options to patients in need. Axcella Health Inc continues to advance its pipeline of potential therapies and collaborate with partners to accelerate the development and commercialization of its groundbreaking solutions.

The main competitors of Axcella Health Inc in the market include companies like Intercept Pharmaceuticals Inc, Madrigal Pharmaceuticals Inc, and Viking Therapeutics Inc.

Axcella Health Inc is primarily active in the biotechnology industry.

The business model of Axcella Health Inc revolves around developing and commercializing novel therapeutic products. Based in the United States, Axcella Health focuses on utilizing the potential of endogenous metabolic modulators (EMMs) to target various biological pathways and address complex diseases. By harnessing the power of EMMs, Axcella Health aims to provide innovative solutions for conditions like liver and muscle disorders, oncology, and metabolic diseases. With a keen focus on research and development, Axcella Health strives to bring forth transformative treatments that can improve patients' lives and contribute to the advancement of medical science.

Axcella Health KGV ir -0,06.

Axcella Health KUV ir 0.

AlleAktien kvalitātes vērtējums Axcella Health ir 2/10.

Pašreiz nevar aprēķināt apgrozījumu Axcella Health.

gaidāmā Axcella Health peļņa ir -15,05 milj. USD.

Axcella Health Inc is a biopharmaceutical company focused on the development of novel, multifunctional drugs. The company has developed a proprietary platform called "axcellerator" that allows it to identify and screen potential drug candidates on a large scale. Axcella Health's business model is primarily focused on licensing its drug candidate identification platform to biotechnology and pharmaceutical companies. The company has also developed its own pipeline of products that it markets itself. Axcella Health targets companies that are in search of new drug candidates and want to accelerate their own research and development. Axcella Health's platform provides these companies with a fast and cost-effective method for identifying drug candidates on a large scale. By utilizing "axcellerator," Axcella Health can quickly identify a large number of potential drugs and then test and screen them for efficacy and safety. Axcella Health has also developed a range of products based on this platform. The products primarily operate in the areas of metabolic health and immunology. These products are all patented and provide the company the opportunity to test its platform in practice while generating revenue through licensing and sales. Axcella Health is currently developing several products, including: - AXA1125: A potential candidate for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). - AXA1957: A potential candidate for the treatment of type 2 diabetes and insulin-dependent diabetes. - AXA2678: A potential candidate for the treatment of cancer and autoimmune diseases. Axcella Health has also partnered with Nestle Health Science to jointly develop new products in the field of metabolic health. Overall, Axcella Health's business model is focused on leveraging the power of its platform and its own expertise in drug research and development to help companies and products worldwide. This model allows Axcella Health to develop a wide range of products while generating revenue, making it a compelling business model for investors and partners.

Axcella Health izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Axcella Health vai uzņēmums nedod dividendes.

Axcella Health ISIN ir US05454B1052.

Axcella Health WKN ir A2PJCG.

Axcella Health simbols ir AXLA.

Pēdējo 12 mēnešu laikā Axcella Health maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Axcella Health plāno maksāt dividendes 0 USD apmērā.

Axcella Health pašreizējā dividendu rentabilitāte ir .

Axcella Health maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Axcella Health pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Axcella Health tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Axcella Health apmērā 0 USD, kas tika izmaksāta 22.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 22.09.2024..

Pēdējās dividendes izmaksa notika 22.09.2024..

Gadā 2023, Axcella Health izmaksāja 0 USD dividendes.

Axcella Health dividendes tiek izmaksātas USD.